HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Greinert, U. Articles by Entzian, P. Search for Related Content PubMed PubMed Citation Articles by Greinert, U. Articles by Entzian, P.

Interleukin-12 as successful adjuvant in tuberculosis treatment

¹ Dept Internal Medicine, and ² Dept Immunology and Cell Biology, Research Centre Borstel

CORRESPONDENCE: U. Greinert, Dept Internal Medicine, Research Centre Borstel, Parkallee 35, D-23845, Borstel, Germany. Fax: 49 4537188313

Keywords: cytokines, interleukin-12, interferon-, tuberculosis

Received: May 29, 2000
Accepted October 13, 2000

Abstract

Interleukin-12 (IL-12) proved to be an effective and successful adjuvant to a standard antituberculotic medication in a patient suffering from progressive clinical tuberculosis (TB).

IL-12 is a potent enhancer of interferon- production which is necessary for killing intracellular bacteria like mycobacteria. This patient's TB was progressive, although sensitivity to first-line antituberculotics was proven and medication was given as directly observed therapy over more than 8 months. The 3-month adjuvant therapy with IL-12 significantly and convincingly improved results.

It is believed that this case, the first in the literature to describe adjuvant interleukin-12 therapy in tuberculosis, strongly encourages the study of adjuvant interleukin-12 therapy on a more systematic basis.

This article has been cited by other articles:

				H. Cho and D. N. McMurray Neutralization of Tumor Necrosis Factor Alpha Suppresses Antigen-Specific Type 1 Cytokine Responses and Reverses the Inhibition of Mycobacterial Survival in Cocultures of Immune Guinea Pig T Lymphocytes and Infected Macrophages Infect. Immun., December 1, 2005; 73(12): 8437 - 8441. [Abstract] [Full Text] [PDF]

				C. G. Feng, D. Jankovic, M. Kullberg, A. Cheever, C. A. Scanga, S. Hieny, P. Caspar, G. S. Yap, and A. Sher Maintenance of Pulmonary Th1 Effector Function in Chronic Tuberculosis Requires Persistent IL-12 Production J. Immunol., April 1, 2005; 174(7): 4185 - 4192. [Abstract] [Full Text] [PDF]

				H. Cho, T. M. Lasco, S. S. Allen, T. Yoshimura, and D. N. McMurray Recombinant Guinea Pig Tumor Necrosis Factor Alpha Stimulates the Expression of Interleukin-12 and the Inhibition of Mycobacterium tuberculosis Growth in Macrophages Infect. Immun., March 1, 2005; 73(3): 1367 - 1376. [Abstract] [Full Text] [PDF]

				D. Nolt and J. L. Flynn Interleukin-12 Therapy Reduces the Number of Immune Cells and Pathology in Lungs of Mice Infected with Mycobacterium tuberculosis Infect. Immun., May 1, 2004; 72(5): 2976 - 2988. [Abstract] [Full Text] [PDF]

				A. Chackerian, J. Alt, V. Perera, and S. M. Behar Activation of NKT Cells Protects Mice from Tuberculosis Infect. Immun., November 1, 2002; 70(11): 6302 - 6309. [Abstract] [Full Text] [PDF]

				G. J. Nau, J. F. L. Richmond, A. Schlesinger, E. G. Jennings, E. S. Lander, and R. A. Young Human macrophage activation programs induced by bacterial pathogens PNAS, February 5, 2002; 99(3): 1503 - 1508. [Abstract] [Full Text] [PDF]